Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Assets (2022 - 2025)

Historic Assets for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $244.7 million.

  • Century Therapeutics' Assets fell 3702.87% to $244.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $244.7 million, marking a year-over-year decrease of 3702.87%. This contributed to the annual value of $353.2 million for FY2024, which is 207.24% down from last year.
  • Latest data reveals that Century Therapeutics reported Assets of $244.7 million as of Q3 2025, which was down 3702.87% from $284.7 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Assets high stood at $550.3 million for Q1 2022, and its period low was $244.7 million during Q3 2025.
  • In the last 4 years, Century Therapeutics' Assets had a median value of $397.6 million in 2023 and averaged $404.3 million.
  • As far as peak fluctuations go, Century Therapeutics' Assets decreased by 17.09% in 2024, and later plummeted by 3702.87% in 2025.
  • Century Therapeutics' Assets (Quarter) stood at $486.5 million in 2022, then decreased by 25.87% to $360.7 million in 2023, then decreased by 2.07% to $353.2 million in 2024, then tumbled by 30.72% to $244.7 million in 2025.
  • Its last three reported values are $244.7 million in Q3 2025, $284.7 million for Q2 2025, and $315.6 million during Q1 2025.